Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 76

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 76
---
 2025 Form 10-Q  |  Page 30

The Company’s income tax expense represents the estimated annual effective tax rate applied to the year-to-date operating results, adjusted for certain discrete tax items.The Company’s effective tax rate for the three and six months ended June 30, 2025 was primarily impacted by costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance.The Company’s effective tax rate for the three and six months ended June 30, 2024 include costs related to non-deductible stock-based compensation, primarily related to expired stock options, and non-deductible executive compensation, partially offset by tax creditsAs of both June 30, 2025 and December 31, 2024, the Company had an income tax payable balance of $5.1 million that was included in other liabilities within the condensed consolidated balance sheet. As of June 30, 2025 and December 31, 2024, the Company had $0.9 million and $0.7 million, respectively, of current income taxes payable that is included in accrued expenses within the condensed consolidated balance sheet. The income tax provision for the year ended December 31, 2025 may be impacted by recent federal legislation known as the One Big Beautiful Bill Act. See Note 18, Subsequent Events, for more information.

NOTE 15—CONTINGENT CONSIDERATION (GAINS) CHARGES, ACQUISITION-RELATED EXPENSES, RESTRUCTURING AND OTHER

Contingent consideration (gains) charges, acquisition-related expenses, restructuring and other for the six months ended June 30, 2025 and 2024 summarized below (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Contingent consideration (gains) charges$(357)$1,509 $(3,032)$(2,297)Restructuring charges— 996 — 6,531 Acquisition-related expenses991 230 2,502 404 Legal settlement— — 7,000 — Total contingent consideration (gains) charges, acquisition-related expenses, restructuring and other$634 $2,735 $6,470 $4,638 Flexion Acquisition Contingent ConsiderationThe Company recognized gains of $0.4 million and $3.0 million related to contingent